Previous 10 | Next 10 |
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that its inaugural 2022 Corporate Transparency Report is now available under the Investors section of the Company’s website, harrowinc.com . The report focuses on Harrow Healt...
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022. ...
Company Actively Dosing Patients for Phase 2 Pivotal Efficacy Study for MELT-300; Full Enrollment Followed by Readout on Topline Data Expected by End of Second Quarter of 2022 Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in ...
Expands and Strengthens Portfolio of Product Offerings for U.S. Ophthalmic Surgical and Acute Care Markets Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced its acquisition of the exclusive U.S. commercialization rights of f...
Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021. The Nasdaq Biotechnology Index (NBI) is designed to meas...
EyePoint Pharmaceuticals (NASDAQ:EYPT) and ImprimisRx, a subsidiary of Harrow Health (NASDAQ:HROW), have expanded an alliance under which Imprimis is now responsible for marketing of Dexycu (dexamethasone intraocular suspension) for post-operative inflammation. ImprimisRx will assume sales an...
WATERTOWN, Mass. and NASHVILLE, Tenn. and CARLSBAD, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, an...
Even though the company failed to fit the analysts' expectations for EPS, the company's financial indicators are growing. The company's gross margin is growing, operating expenses are decreasing, and revenue growth rate maintains a positive trend. We expect the company continues to in...
The following slide deck was published by Harrow Health, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Harrow Health, Inc. 2021 Q3 - Results - Earnings Call Presentation
Harrow Health, Inc. (HROW) Q3 2021 Earnings Conference Call November 9, 2021 4:45 PM ET Company Participants Jamie Webb – Director of Communications and Investor Relations Mark L. Baum – Chief Executive Officer Andrew Boll – Chief Financial Officer Conference Call Partici...
News, Short Squeeze, Breakout and More Instantly...
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...